Your browser doesn't support javascript.
loading
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Turner, N; Ciruelos, E M; Muñoz, M; Bermejo, B; Margeli, M; Anton, A; Kahan, Z; Csöszi, T; Casas, M I; Murillo, L; Morales, S; Alba, E; Gal-Yam, E; Guerrero-Zotano, A; Calvo, L; de la Haba-Rodriguez, J; Ramos, M; Alvarez, I; Garcia-Palomo, A; Huang Bartlett, C; Koehler, M; Caballero, R; Corsaro, M; Huang, X; Garcia-Sáenz, J A; Chacón, J I; Swift, C; Thallinger, C; Gil-Gil, M.
Afiliación
  • Martin M; Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Medicine Department, Universidad Complutense, Madrid, Spain; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain. Electronic address: mmartin@geicam.
  • Zielinski C; Medical Oncology, Central European Cancer Center, Wiener Privatklinik Hospital, Vienna, Austria; CECOG Central European Cooperative Oncology Group, Vienna, Austria.
  • Ruiz-Borrego M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
  • Carrasco E; GEICAM Spanish Breast Cancer Group, Madrid, Spain.
  • Turner N; Institute of Cancer Research and Royal Marsden, London, UK.
  • Ciruelos EM; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical Oncology, HM Hospitales Madrid, Madrid, Spain; SOLTI Group on Breast Cancer Research, Barcelona, Spain.
  • Muñoz M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors (IDIBAPS), Barcelona, Spain.
  • Bermejo B; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain; Biomedical Research Institute INCLIVA, Valencia, Spain.
  • Margeli M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; B-ARGO Group, Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Anton A; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Kahan Z; Department of Oncotherapy, University of Szeged, Szeged, Hungary.
  • Csöszi T; Department of Oncology, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary.
  • Casas MI; GEICAM Spanish Breast Cancer Group, Madrid, Spain.
  • Murillo L; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clínico de Zaragoza Lozano Blesa, Zaragoza, Spain.
  • Morales S; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Arnau de Vilanova, Lleida, Spain.
  • Alba E; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; UGCI Medical Oncology, Hospitales Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
  • Gal-Yam E; Department of Oncology, Institute of Oncology, Sheba Medical Center, Tel-Hashomer, Israel.
  • Guerrero-Zotano A; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
  • Calvo L; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Complejo Hospitalario A Coruña, Coruña, Spain.
  • de la Haba-Rodriguez J; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Reina Sofia, Córdoba; Instituto Maimonides de Investigación Biomédica (IMIBIC); Universidad de Córdoba, Córdoba, Spain.
  • Ramos M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro Oncológico de Galicia, A Coruña, Coruña, Spain.
  • Alvarez I; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Donostia-Biodonostia, San Sebastián, Spain.
  • Garcia-Palomo A; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital de León, León, Spain.
  • Huang Bartlett C; Pfizer, USA.
  • Koehler M; Pfizer, USA; Repare Therapeutics, Cambridge, USA.
  • Caballero R; GEICAM Spanish Breast Cancer Group, Madrid, Spain.
  • Corsaro M; Pfizer, Italy.
  • Huang X; Pfizer, USA.
  • Garcia-Sáenz JA; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain.
  • Chacón JI; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain.
  • Swift C; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden, London, UK.
  • Thallinger C; CECOG Central European Cooperative Oncology Group, Vienna, Austria; Department of Oncology, Medical University of Vienna, Department of Oncology, Vienna, Austria.
  • Gil-Gil M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Institut Català d'Oncologia (ICO) & IDIBELL, L'Hospitalet, Barcelona, Spain.
Ann Oncol ; 32(4): 488-499, 2021 04.
Article en En | MEDLINE | ID: mdl-33385521
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Inhibidores de la Aromatasa Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Inhibidores de la Aromatasa Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido